The conclusion of the FUTURE study1 by Mohamed Abdel-Fattah and colleagues—that routine urodynamics in women with refractory overactive bladder (r-OAB) is unjustified—is unsurprising. What is ...

Britain's counter-radicalisation scheme Prevent recorded a 27% rise in referrals last year, with about a third of those ...

Acute kidney injury (AKI) is among the most common organ failures observed in the hospital and can irrevocably alter the ...

Alvotech announced on August 21, 2025, that the European Commission had approved AVT06 as a biosimilar to Eylea ®, for marketing in the European Economic Area. The UK Medicines and Healthcare products ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the ...

Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.

Hydrohertz’s technology is its patented Dectravalve, a compact, intelligent, multi-zone valve system that delivers precise ...

A doctor has shared a simple 15-second trick that'll help ease your sore throat without having to visit the chemist ...

Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds ...